# Alliance Pharma reports mixed FY2024 results

- Link: https://www.directorstalkinterviews.com/alliance-pharma-reports-mixed-fy2024-results/4121185247
- Published: 2025-01-31T07:19:35+00:00
- Author: Amilia Stone

**Alliance Pharma plc** (LON: APH), the international healthcare group, has announced
its unaudited trading update for the year ended 31 December 2024, ahead of the announcement
of the Group’s audited results.

The Group delivered see-through^(1) revenues in the Period of £180.3m (FY23: £182.7m),
down 1% versus the prior period and up 1% at constant exchange rates (CER). Whilst
revenues declined in some of our brands, we delivered strong performance in Kelo-
Cote, MacuShield, Hydromol and Forceval.

Kelo-Cote franchise revenues grew 6% CER to £65.4m (FY23: £63.2m) in-line with previous
guidance of mid-single digit revenue growth. Whilst we remain committed to moving
to smaller, more regular orders in China, this is taking longer than we anticipated.
Nizoral revenues declined 21% CER to £16.4m (FY23: £21.7m) due to the timing of 
distributor orders. Amberen revenues declined 7% CER to £10.1m (FY23: £11.2m). Other
Consumer declined 2% CER to £38.8m (FY23: £40.3m) with a strong performance in MacuShield(
+11% CER) offset by weakness in Lefuzhi and Ashton & Parsons. Consequently, total
see-through Consumer Healthcare revenues declined 2% CER to £130.7m (FY23: £136.4m).

Prescription Medicine revenues increased 8% CER to £49.6m (FY23: £46.3m). Forceval
delivered another solid performance with revenues up 20% CER to £7.9m (FY23: £6.6m),
Hydromol revenues increased 14% CER to £10.3m (FY23: £9.0m) and other prescription
medicine revenues showed strong recovery as previously out of stock products became
available.

The Board continues to anticipate that underlying Group profit in FY 2024 will be
in line with FY 2023.

> **Nick Sedgwick, Chief Executive Officer of Alliance Pharma, commented**:
> “I am pleased that performance in 2024 is in-line with expectations. Whilst we
> have much to do as we work on our transformation plans, I am confident that our
> strong portfolio of clinically differentiated brands will deliver predictable 
> organic revenue growth over the mid-long term.”

_^(1)_ _See-through revenue includes sales from Nizoral as if they had been invoiced
by Alliance as principal. For statutory accounting purposes the product margin relating
to Nizoral sales made on an agency basis is included within Revenue, in line with
IFRS 15._

Share on:
